Azlocillin in the treatment of serious infection with Pseudomonas aeruginosa

Publisher Website
Google Scholar
Abstract
Azlocillin, an acylureidopenicillin that recently became available in the United Kingdom, is considerably more active in vitro than other penicillins against Pseudomonas aeruginosa. During the past two years we have used it to treat 24 patients with serious pseudomonas infection, either alone or in combination with an aminoglycoside, usually gentamicin. In the immunocompromised and often neutropenic patients there was, predictably, a poor response, but good results were seen in other patients with infections that included osteomyelitis, meningitis and pneumonia. One patient developed mild diarrhoea and another had a severe hypersensitivity reaction whilst receiving azlocillin and tobramycin. Azlocillin is a useful new anti-pseudomonal antimicrobial.

This publication has 3 references indexed in Scilit: